Dose optimization of infliximab is required more frequently in ulcerative colitis than in Crohn's disease cases, according to a study published in Journal of Crohn's and Colitis.
Here are five things to know:
1. Researchers used an infusion center database to identify cases in which patients received infliximab for treatment of irritable bowel disease.
2. Approximately, 412 cases were included in the study.
3. Of the 412 cases, 52.7 percent required at least one dose optimization.
4. Dose optimization was more common in ulcerative colitis (67.2 percent) than in Crohn's disease (46.3 percent).
5. The median time to dose optimization was 7 months ulcerative colitis cases and 27 months Crohn's disease cases.